Douglass Winthrop Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.25M | Buy |
52,079
+2,874
| +6% | +$75.2K | 0.02% | 156 |
|
|
2026
Q1 | $1.38M | Sell |
49,205
-2,562
| -5% | -$68.2K | 0.03% | 136 |
|
|
2025
Q4 | $1.29M | Buy |
51,767
+6,198
| +14% | +$156K | 0.02% | 138 |
|
|
2025
Q3 | $1.16M | Sell |
45,569
-26,663
| -37% | -$658K | 0.02% | 144 |
|
|
2025
Q2 | $1.75M | Sell |
72,232
-10,544
| -13% | -$246K | 0.03% | 113 |
|
|
2025
Q1 | $2.1M | Sell |
82,776
-3,000
| -3% | -$78.5K | 0.04% | 106 |
|
|
2024
Q4 | $2.28M | Buy |
85,776
+37,653
| +78% | +$1.02M | 0.04% | 103 |
|
|
2024
Q3 | $1.39M | Buy |
48,123
+6,816
| +17% | +$199K | 0.03% | 119 |
|
|
2024
Q2 | $1.16M | Sell |
41,307
-3,940
| -9% | -$108K | 0.02% | 124 |
|
|
2024
Q1 | $1.26M | Sell |
45,247
-3,360
| -7% | -$93.2K | 0.03% | 122 |
|
|
2023
Q4 | $1.4M | Sell |
48,607
-6,331
| -12% | -$191K | 0.03% | 108 |
|
|
2023
Q3 | $1.82M | Sell |
54,938
-4,999
| -8% | -$177K | 0.05% | 95 |
|
|
2023
Q2 | $2.2M | Sell |
59,937
-2,100
| -3% | -$81.7K | 0.05% | 92 |
|
|
2023
Q1 | $2.53M | Buy |
62,037
+565
| +0.9% | +$24.4K | 0.07% | 86 |
|
|
2022
Q4 | $3.15M | Sell |
61,472
-367
| -0.6% | -$17.6K | 0.09% | 79 |
|
|
2022
Q3 | $2.71M | Hold |
61,839
| – | – | 0.08% | 82 |
|
|
2022
Q2 | $3.24M | Buy |
61,839
+4,035
| +7% | +$206K | 0.09% | 76 |
|
|
2022
Q1 | $2.99M | Buy |
57,804
+200
| +0.3% | +$10.4K | 0.07% | 86 |
|
|
2021
Q4 | $3.4M | Buy |
57,604
+4,845
| +9% | +$240K | 0.08% | 87 |
|
|
2021
Q3 | $2.27M | Sell |
52,759
-433
| -0.8% | -$19.2K | 0.06% | 104 |
|
|
2021
Q2 | $2.08M | Sell |
53,192
-188
| -0.4% | -$7.31K | 0.05% | 107 |
|
|
2021
Q1 | $1.93M | Sell |
53,380
-935
| -2% | -$33.2K | 0.05% | 107 |
|
|
2020
Q4 | $2M | Sell |
54,315
-775
| -1% | -$28.4K | 0.06% | 97 |
|
|
2020
Q3 | $1.92M | Sell |
55,090
-622
| -1% | -$21.8K | 0.06% | 87 |
|
|
2020
Q2 | $1.73M | Buy |
55,712
+5,617
| +11% | +$191K | 0.06% | 87 |
|
|
2020
Q1 | $1.55M | Sell |
50,095
-14,905
| -23% | -$508K | 0.07% | 90 |
|
|
2019
Q4 | $2.42M | Sell |
65,000
-4,173
| -6% | -$149K | 0.09% | 86 |
|
|
2019
Q3 | $2.36M | Buy |
69,173
+12,234
| +21% | +$445K | 0.09% | 81 |
|
|
2019
Q2 | $2.34M | Sell |
56,939
-712
| -1% | -$28.3K | 0.09% | 83 |
|
|
2019
Q1 | $2.32M | Buy |
57,651
+1,119
| +2% | +$44.8K | 0.1% | 85 |
|
|
2018
Q4 | $2.34M | Buy |
56,532
+225
| +0.4% | +$9.34K | 0.12% | 86 |
|
|
2018
Q3 | $2.35M | Sell |
56,307
-2,663
| -5% | -$103K | 0.1% | 87 |
|
|
2018
Q2 | $2.03M | Buy |
58,970
+4,781
| +9% | +$163K | 0.09% | 103 |
|
|
2018
Q1 | $1.82M | Sell |
54,189
-10,963
| -17% | -$377K | 0.09% | 110 |
|
|
2017
Q4 | $2.24M | Buy |
65,152
+5,988
| +10% | +$204K | 0.12% | 85 |
|
|
2017
Q3 | $2M | Buy |
59,164
+6,584
| +13% | +$212K | 0.12% | 88 |
|
|
2017
Q2 | $1.68M | Buy |
52,580
+117
| +0.2% | +$3.69K | 0.1% | 88 |
|
|
2017
Q1 | $1.7M | Sell |
52,463
-12,615
| -19% | -$398K | 0.11% | 91 |
|
|
2016
Q4 | $2M | Buy |
65,078
+6,020
| +10% | +$184K | 0.14% | 77 |
|
|
2016
Q3 | $1.9M | Buy |
59,058
+1,909
| +3% | +$63.8K | 0.13% | 81 |
|
|
2016
Q2 | $1.91M | Buy |
57,149
+168
| +0.3% | +$5.36K | 0.13% | 80 |
|
|
2016
Q1 | $1.6M | Sell |
56,981
-3,304
| -5% | -$94.4K | 0.12% | 89 |
|
|
2015
Q4 | $1.85M | Sell |
60,285
-23,613
| -28% | -$743K | 0.14% | 88 |
|
|
2015
Q3 | $2.5M | Sell |
83,898
-6,456
| -7% | -$207K | 0.2% | 75 |
|
|
2015
Q2 | $2.98M | Hold |
90,354
| – | – | 0.23% | 69 |
|
|
2015
Q1 | $2.98M | Buy |
90,354
+37,657
| +71% | +$1.2M | 0.23% | 69 |
|
|
2014
Q4 | $1.56M | Buy |
52,697
+7,863
| +18% | +$225K | 0.14% | 79 |
|
|
2014
Q3 | $1.26M | Sell |
44,834
-2,485
| -5% | -$69.7K | 0.12% | 84 |
|
|
2014
Q2 | $1.33M | Sell |
47,319
-3,918
| -8% | -$112K | 0.12% | 81 |
|
|
2014
Q1 | $1.56M | Sell |
51,237
-3,096
| -6% | -$92.3K | 0.15% | 71 |
|
|
2013
Q4 | $1.58M | Sell |
54,333
-648
| -1% | -$18.9K | 0.16% | 67 |
|
|
2013
Q3 | $1.5M | Buy |
54,981
+2,510
| +5% | +$68.3K | 0.17% | 67 |
|
|
2013
Q2 | $1.39M | Buy |
+52,471
| New | +$1.45M | 0.17% | 69 |
|
Other funds holding PFE
Douglass Winthrop Advisors's PFE Position: Q2 2026 in Review
Douglass Winthrop Advisors increased its Pfizer (PFE) stake by 5.8% in Q2 2026, buying an estimated $75.2K and bringing the position to 52,079 shares worth $1.25M. The position accounts for 0.02% of the portfolio, ranked #156.
Douglass Winthrop Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.4M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Douglass Winthrop Advisors held 52,079 shares of Pfizer worth $1.25M as of Q2 2026.
- Douglass Winthrop Advisors bought 2,874 Pfizer shares in Q2 2026, an estimated $75.2K.
- Pfizer made up 0.02% of Douglass Winthrop Advisors's portfolio in Q2 2026, its #156 holding.
- Douglass Winthrop Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
- Douglass Winthrop Advisors's Pfizer position peaked at $3.4M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Douglass Winthrop Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.